证券代码：002873 证券简称：新天药业 公告编号：2019-074 贵阳新天药业股份有限公司 关于参加2019年贵州上市公司投资者网上 集体接待日活动的公告 | --- | |---------------------------------------------------------------------------------------------------| | 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 \n记载、误导性陈述或者重大遗漏。 | | | | 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融资 | | 计划、股权激励、可持续发展等投资者所关心的问题，公司定于 | | 日下午 14:00-17:00 参加由贵州证监局主办，贵州证券业协会、深圳市全景网络 | | 有限公司协办的主题为"股东来了——构建和谐投资者关系" | | 公司投资者网上集体接待日活动。现将有关事项公告如下： | | 本次集体接待日网上交流网址：投资者可以登录 http://rs.p5w.net | | 区页面参与交流。 | | 出席本次集体接待日的人员有：公司董事长、总经 ...

贵阳新天药业股份有限公司 2019 年第一季度报告全文 贵阳新天药业股份有限公司 2019 年第一季度报告 2019-063 2019 年 04 月 1 贵阳新天药业股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人董大伦、主管会计工作负责人袁列萍及会计机构负责人(会计主 管人员)袁列萍声明：保证季度报告中财务报表的真实、准确、完整。 2 贵阳新天药业股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益 项目界定为经常性损益的项目的情形。 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 162 ...

Financial Performance - The company's operating revenue for 2018 was CNY 694,259,400.60, representing a 1.84% increase compared to CNY 681,714,129.26 in 2017[17]. - The net profit attributable to shareholders for 2018 was CNY 70,975,496.22, which is a 7.35% increase from CNY 66,116,844.06 in 2017[17]. - The net profit after deducting non-recurring gains and losses decreased by 6.20% to CNY 59,070,611.08 in 2018 from CNY 62,973,693.63 in 2017[17]. - The net cash flow from operating activities was CNY 47,592,579.48, down 23.31% from CNY 62,060,035.55 in the previous year[17]. - The basic earnings per share for 2018 was CNY 0.6061, a decrease of 3.84% from CNY 0.6303 in 2017[17]. - The total assets at the end of 2018 were CNY 984,313,099.51, reflecting a 14.94% increase from CNY 856,403,946.15 at the end of 2017[18]. - The net assets attributable to shareholders increased by 5.89% to CNY 658,718,793.62 at the end of 2018 from CNY 622,105,344.44 at the end of 2017[18]. - The weighted average return on net assets decreased to 10.91% in 2018 from 13.98% in 2017, indicating a decline in profitability[17]. Revenue Breakdown - Total revenue for the year was 201,781,886.88 CNY in Q3, with a quarterly revenue of 172,254,916.38 CNY in Q4[22]. - Net profit attributable to shareholders was 32,126,642.90 CNY in Q3, but dropped to 5,966,399.52 CNY in Q4[22]. - The net cash flow from operating activities reached 36,746,112.42 CNY in Q3, while it decreased to 2,659,371.20 CNY in Q4[22]. - The main business revenue was CNY 693.64 million, accounting for 99.91% of total revenue, with a growth of 1.80% compared to the previous year[46]. - The revenue from the main product, Kuntai Capsule, was CNY 284.28 million, accounting for 40.95% of total revenue, with a growth of 3.03%[46]. Research and Development - The company has established a strong R&D team and a tiered project structure to support future growth[27]. - The company holds 40 invention patents and has obtained 11 national new drug certificates, indicating a strong focus on R&D[38]. - Research and development expenses increased by 37.91% to ¥31,833,436.04 in 2018, primarily due to increased R&D activities[56]. - The number of R&D personnel increased by 13.24% to 154, while R&D investment amounted to ¥31,968,464.18, representing 4.60% of operating revenue[60]. Market Strategy and Operations - The company plans to leverage its unique R&D capabilities and rich herbal resources in Guizhou Province to develop modern traditional Chinese medicine[43]. - The company has 50+ drug production licenses and 13 exclusive varieties, with leading products being unique in the domestic market[27]. - The sales team consists of over 800 members, covering over 10,000 hospitals and establishing stable business relationships with over 1,000 medical commercial units[40]. - The company’s marketing strategy emphasizes professional promotion and service-oriented sales, enhancing trust among clinical medical personnel[39]. Investment and Financing - The company plans to expand its market presence and enhance product offerings through strategic investments and partnerships in the pharmaceutical technology sector[69]. - The total amount of funds raised in the IPO was 317.02 million RMB, with a net amount of 289.69 million RMB after deducting issuance costs of 27.33 million RMB[74]. - The company has committed to invest 73.37 million RMB in the new traditional Chinese medicine extraction production project, with 20.42% of the investment completed by the end of the reporting period[76]. - The company has engaged in significant equity investments, including a new establishment in the pharmaceutical sector with a capital of $20 million, holding a 51% stake[69]. Dividend Policy - The company plans to distribute a cash dividend of CNY 0.50 per 10 shares (including tax) to all shareholders[4]. - The cash dividend amount was CNY 5,854,800, representing 8.25% of the net profit attributable to ordinary shareholders[96]. - The total cash dividend (including other methods) for 2018 was CNY 21,829,285.93, which accounted for 32.51% of the distributable profit of CNY 67,139,493.97[97]. - The cash dividend payout ratio for 2018 was the lowest at 20% due to significant capital expenditure plans[97]. Corporate Governance - The company has established measures to stabilize its stock price, including potential share buybacks if the stock price falls below 120% of the latest audited net asset value per share[106]. - The company has committed to transparency by announcing any shareholding reductions three trading days in advance, detailing the amount and execution period[101]. - The company has not engaged in any related party transactions that would compromise its financial integrity, maintaining a clear separation from its controlling shareholders[103]. - The company’s management team includes several key individuals who are responsible for ensuring the integrity of financial reporting and compliance[118]. Social Responsibility and Environmental Impact - The company donated a total of 1 million yuan for medical assistance and educational support in 2018, including 100,000 yuan to Nanjing Medical University for medical aid[149]. - The company has established a wastewater treatment capacity of 2,000 tons per day at the old plant and 720 tons per day at the new plant, ensuring compliance with environmental standards[155]. - The company actively participates in social welfare activities, emphasizing environmental protection and energy consumption reduction[147]. - The company has established a robust environmental protection framework, with all pollution control facilities operating in compliance with regulatory standards[154]. Employee and Management Structure - The total number of employees in the company is 1,521, with 1,367 in the parent company and 154 in major subsidiaries[200]. - The professional composition includes 880 sales personnel, 260 production personnel, 230 technical personnel, 40 financial personnel, and 111 administrative personnel[200]. - The current management team includes 12 members, with a mix of directors and vice presidents[199]. - The average age of the current management team is approximately 48 years[199].

贵阳新天药业股份有限公司 2018 年第三季度报告正文 证券代码：002873 证券简称：新天药业 公告编号：2018-091 贵阳新天药业股份有限公司 2018 年第三季度报告正文 1 贵阳新天药业股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人董大伦、主管会计工作负责人袁列萍及会计机构负责人(会计主 管人员)袁列萍声明：保证季度报告中财务报表的真实、准确、完整。 2 贵阳新天药业股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 994,236,389.98 | 856,403,946.15 | | 16.09% | | 归属于上市 ...

Financial Performance - The company's operating revenue for the first half of 2018 was ¥320,222,597.34, a decrease of 1.50% compared to the same period last year[18]. - The net profit attributable to shareholders of the listed company was ¥32,882,453.80, an increase of 10.95% year-on-year[18]. - The net profit after deducting non-recurring gains and losses was ¥29,229,864.87, reflecting a growth of 3.43% compared to the previous year[18]. - The net cash flow from operating activities was ¥8,187,095.86, down 51.69% from the same period last year[18]. - The total assets at the end of the reporting period were ¥942,703,205.82, representing a 10.08% increase from the end of the previous year[18]. - The net assets attributable to shareholders of the listed company were ¥654,562,798.24, up 5.22% from the previous year[18]. - The basic earnings per share decreased by 12.16% to ¥0.4774 compared to the same period last year[18]. - The weighted average return on net assets was 5.15%, down 3.61% from the previous year[18]. - The gross profit margin for the main business was 78.64%, down 2.80% from the previous year[47]. - The company reported a significant reduction in financial expenses by 88.84% to CNY 525,088.58, due to loan interest subsidies[44]. Research and Development - The company holds 40 invention patents and has obtained 11 national new drug certificates, indicating a strong focus on research and development[38]. - The company has a structured R&D project framework that supports sustainable growth and innovation in product development[38]. - Research and development expenses increased by 54.99% to CNY 17.20 million, reflecting enhanced R&D activities[44]. Marketing and Sales - The company has established a professional marketing team that enhances academic promotion and service marketing, improving trust among clinical medical personnel[39]. - The company’s main products are included in the national medical insurance directory, which supports their market expansion and sales growth[30][32][33][36]. - The company established 99 regional offices across 30 provinces, covering over 9,000 hospitals[40]. - The company has a strong marketing management system that adapts to changes in the national medical reform and traditional Chinese medicine sales trends[39]. Investments and Projects - The company has invested ¥624.63 million in the reporting period, with a cumulative investment of ¥11,238.57 million[60]. - The new Chinese medicine extraction production line project has a total commitment of ¥7,337 million, with 20.42% of the investment completed[62]. - The Chinese medicine preparation product capacity enhancement project has a total commitment of ¥9,958 million, with 7.14% of the investment completed[62]. - The research and development center construction project has a total commitment of ¥2,700 million, with 21.37% of the investment completed[62]. - The market marketing network construction project has a total commitment of ¥3,000 million, with 82.59% of the investment completed[62]. Cash Flow and Liquidity - The company’s cash and cash equivalents decreased by 80.81% to CNY 50.33 million, largely influenced by previous fundraising activities[45]. - The ending cash and cash equivalents balance was 136,830,915.63 CNY, a decrease of 57.8% from 324,715,873.27 CNY in the previous period[151]. - The net cash flow from operating activities was 8,187,095.86 CNY, a decrease of 51.7% compared to 16,948,204.73 CNY in the previous period[150]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 10,768[119]. - The largest shareholder, Guiyang Xintian Biological Technology Development Co., Ltd., holds 30,265,760 shares, accounting for 43.94% of total shares[119]. - The total number of shares held by the top ten shareholders is significant, with the top four alone holding over 66% of the shares[119]. - The company has not undergone any changes in its controlling shareholder during the reporting period[121]. Environmental and Regulatory Compliance - The company has implemented pollution prevention measures with wastewater treatment facilities at both old and new plants, with the old plant having a daily treatment capacity of 2,000 tons and the new plant 720 tons[102]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[100]. - The company has established emergency response plans for environmental incidents, with both new and old plants having their plans registered[104]. Risks and Challenges - The company faces risks related to potential price reductions in pharmaceuticals due to government policies, which could impact profit margins[72]. - Environmental risks may increase due to potential new regulations and higher standards, impacting the company's costs[74]. - The company aims to reduce the proportion of environmental costs in total costs by expanding sales scale[75]. Corporate Governance - The half-year financial report has not been audited[82]. - The company has not engaged in any significant related party transactions during the reporting period[87]. - There were no major asset or equity sales during the reporting period[67][68].

Financial Performance - The company's operating revenue for 2017 was ¥681,714,129.26, representing a 7.66% increase compared to ¥633,186,158.18 in 2016[16] - The net profit attributable to shareholders for 2017 was ¥66,116,844.06, which is a 15.85% increase from ¥57,069,484.54 in 2016[16] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥62,973,693.63, up 14.19% from ¥55,149,590.51 in 2016[16] - The net cash flow from operating activities was ¥62,060,035.55, a slight increase of 1.17% from ¥61,343,778.42 in 2016[16] - Total revenue for the year was approximately ¥681 million, with a quarterly breakdown of ¥147 million, ¥178 million, ¥200 million, and ¥156 million respectively[21] - Net profit attributable to shareholders for the year was approximately ¥66 million, with quarterly figures of ¥15 million, ¥14 million, ¥32 million, and ¥4 million[21] - The company achieved a revenue of 681.71 million yuan in 2017, representing a year-on-year growth of 7.66%[40] - The net profit attributable to shareholders was 66.12 million yuan, an increase of 15.85% compared to the previous year[40] - The production volume of traditional Chinese medicine reached 31.44 million boxes, up 11.93% from 28.09 million boxes in 2016[48] - The sales volume increased to 30.24 million boxes, reflecting a growth of 9.75% from 27.55 million boxes in 2016[48] Assets and Liabilities - The total assets at the end of 2017 were ¥856,403,946.15, reflecting a 55.84% increase from ¥549,538,195.49 at the end of 2016[17] - The net assets attributable to shareholders increased by 122.81% to ¥622,105,344.44 from ¥279,206,513.66 in 2016[17] - The company's debt-to-asset ratio improved from 49.19% to 27.36% during the reporting period[170] - Total assets at the end of the reporting period reached CNY 856 million, representing a 55.84% increase, while net assets grew by 122.81% to CNY 622 million[170] Research and Development - The company holds 39 invention patents and has obtained 11 new drug certificates, indicating a strong focus on research and development[35] - The company emphasizes the importance of R&D as a core competitive advantage, with a structured approach to innovation and product development[35] - Research and development (R&D) investment increased by 17.13% to ¥23,595,669.15, representing 3.46% of operating revenue[61] - The number of R&D personnel rose to 136, a 1.49% increase from the previous year[61] - The company is advancing several new drug projects, including "术愈通颗粒" and "龙芩盆腔舒颗粒," with clinical studies completed and production application materials being prepared[58][59] Marketing and Sales Strategy - The company expanded its marketing team, focusing on professional academic promotion to enhance trust among clinical medical staff[37] - The company’s marketing strategy emphasizes service-oriented sales and professional promotion to adapt to new market conditions[40] - The company plans to initiate large-scale academic promotion activities for its proprietary products, which include several unique formulations with good market prospects[90] - The company plans to enhance its sales team and channel management to expand its product sales regions and improve marketing capabilities[90] Investment and Capital Management - The company raised a total of RMB 31,702.02 million through the issuance of 17.22 million A-shares at a price of RMB 18.41 per share, with a net amount of RMB 28,969.23 million after deducting issuance costs of RMB 2,732.79 million[79] - The company has invested RMB 1,247.51 million (17.00% of the total) in the new traditional Chinese medicine extraction production line project, which is currently under construction[82] - The company has allocated RMB 2,337.73 million (77.92% of the total) for the construction of a marketing network, which is expected to be completed by June 2020[82] - The company has fully utilized RMB 5,974.23 million (100.00% of the total) for the project of supplementing working capital and repaying bank loans[82] Corporate Governance and Shareholder Relations - The company has established a fair and competitive talent and compensation system to enhance employee rights and benefits[152] - The company emphasizes the protection of investor rights, ensuring equal treatment and information access for all shareholders[151] - The company has maintained a consistent cash dividend policy over the past three years, with cash dividends of 9.82 million yuan in 2015, 11.88 million yuan in 2016, and 13.78 million yuan in 2017[101] - The company will publicly disclose reasons for not implementing stabilization measures and apologize to shareholders if such measures are not taken[42] Environmental and Social Responsibility - The company has implemented environmental protection measures and is classified as a key pollutant discharge unit[156] - The company has actively participated in social welfare activities, promoting environmental protection and resource conservation[152] - The company donated 50,000 yuan for poverty alleviation efforts in Tonggu County, addressing issues faced by "three stay-at-home" individuals and disabled persons[153] - A total of 100,000 yuan was donated to improve teacher resources at a local school in Zunyi City, Guizhou Province[153] Future Outlook and Strategic Initiatives - The company expects a revenue growth guidance of 10% for the upcoming fiscal year, projecting revenues to reach approximately 1.32 billion RMB[106] - New product development includes the launch of two innovative drug formulations, expected to contribute an additional 200 million RMB in revenue[107] - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share within three years[106] - A strategic acquisition of a local biotech firm is anticipated to enhance the company's R&D capabilities and is expected to close by Q3 2018[105]

Financial Performance - The company's revenue for Q1 2018 was ¥156,411,465.16, representing a 6.41% increase compared to ¥146,986,626.23 in the same period last year[8] - Net profit attributable to shareholders was ¥17,125,823.30, up 11.25% from ¥15,393,861.17 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥16,890,823.30, reflecting a 17.73% increase from ¥14,346,626.73 in the previous year[8] - The estimated net profit for the first half of 2018 is projected to be between 32.60 million yuan and 37.05 million yuan, representing a growth of 10% to 25% compared to 29.64 million yuan in the same period of 2017[19] - The increase in net profit is primarily attributed to business growth[19] Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 94.68%, amounting to ¥1,341,814.45 compared to ¥25,232,573.52 in the same period last year[8] - Total assets at the end of the reporting period were ¥914,718,605.96, a 6.81% increase from ¥856,403,946.15 at the end of the previous year[8] - Prepayments increased by 98.81% to ¥14,371,785.13, primarily due to increased payments for project research and equipment[15] - Other receivables surged by 202.73% to ¥18,674,742.50, mainly due to an increase in market reserve funds[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,972[10] - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., held 43.94% of the shares, totaling 30,265,766 shares[11] Corporate Governance - The company reported no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[18] - There were no violations regarding external guarantees during the reporting period[22] - The company did not experience any non-operating fund occupation by controlling shareholders or related parties during the reporting period[23] - No research, communication, or interview activities were conducted during the reporting period[24] Profit Distribution - The company proposed a profit distribution plan for 2017, distributing a cash dividend of 2 yuan per 10 shares and a capital reserve increase of 10 shares for every 10 shares held[16] Financial Assets - The fair value of financial assets includes an initial investment of 1,255,000 yuan, with a current fair value change of 429,250 yuan, leading to a total amount of 7,185,000 yuan[21] Return on Equity - The company's weighted average return on equity decreased to 2.72% from 5.08% year-on-year, a decline of 2.36%[8]

2 贵阳新天药业股份有限公司 2017 年第三季度报告正文 证券代码：002873 证券简称：新天药业 公告编号：2017-041 贵阳新天药业股份有限公司 2017 年第三季度报告正文 1 贵阳新天药业股份有限公司 2017 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人董大伦、主管会计工作负责人袁列萍及会计机构负责人(会计主 管人员)袁列萍声明：保证季度报告中财务报表的真实、准确、完整。 贵阳新天药业股份有限公司 2017 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 919,252,761.88 | | 549,538,195.49 | 67.28% | | 归属于上市 ...

Financial Performance - The company's operating revenue for the first half of 2017 was CNY 325,086,454.48, representing an increase of 11.01% compared to CNY 292,853,340.84 in the same period last year[17]. - The net profit attributable to shareholders of the listed company was CNY 29,636,748.72, up 19.35% from CNY 24,832,384.58 year-on-year[17]. - The net profit after deducting non-recurring gains and losses was CNY 28,260,139.29, reflecting a growth of 14.21% compared to CNY 24,744,834.58 in the previous year[17]. - The basic earnings per share increased to CNY 0.54, a rise of 12.50% from CNY 0.48 in the same period last year[17]. - The total operating revenue for the first half of 2017 was CNY 325,158,991.60, an increase of 11.0% compared to CNY 292,928,295.88 in the same period last year[151]. - The net profit for the first half of 2017 was CNY 18,470,837.92, down 34.1% from CNY 28,018,761.48 in the previous year[151]. - The total comprehensive income for the first half of 2017 was CNY 18,483,587.92, down 34.1% from CNY 28,018,761.48 in the previous year[153]. - The company reported a total comprehensive income of CNY 29,649,498.72 for the period, reflecting positive operational performance[162]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 862,484,335.37, marking a significant increase of 56.95% from CNY 549,538,195.49 at the end of the previous year[17]. - The company's total assets reached CNY 883,206,997.47, compared to CNY 575,701,355.73 at the beginning of the year, indicating a growth of 53.4%[145]. - Total liabilities increased to CNY 275,817,836.27 from CNY 270,331,681.83, a rise of approximately 2.0%[140]. - The total liabilities were CNY 304,638,729.01, slightly up from CNY 293,427,161.91, showing an increase of 3.7%[145]. - The company's equity attributable to shareholders rose to CNY 578,568,268.46 from CNY 282,274,193.82, reflecting a growth of 105.5%[145]. - The company's total equity increased to CNY 578,568,268.46 by the end of the reporting period, up from CNY 282,274,193.82 at the beginning of the year, representing a growth of approximately 104.5%[174]. Cash Flow - The net cash flow from operating activities was CNY 16,948,204.73, down 26.18% from CNY 22,957,972.12 in the same period last year[17]. - The cash flow from operating activities decreased by 26.18% to 16.95 million yuan, primarily due to increased expense payments[45]. - The cash and cash equivalents increased significantly to CNY 307,708,945.02 from CNY 31,502,407.00, marking a rise of 876.5%[143]. - The total cash and cash equivalents at the end of the period reached CNY 307,708,945.02, up from CNY 32,108,517.32 at the end of the previous period, showing a strong liquidity position[160]. - The net cash flow from investment activities was -CNY 39,563,197.26, compared to -CNY 16,204,774.51 in the previous period, indicating a significant increase in cash outflow for investments[160]. - The net cash flow from financing activities was CNY 287,214,682.19, a substantial improvement from -CNY 28,461,102.95 in the prior period, reflecting successful capital raising efforts[160]. Investments and Projects - The company has invested in the "Chinese Medicine Preparation Product Capacity Enhancement Project" and the technology upgrade of the Chinese medicine extraction production line[26]. - The company has committed a total investment of RMB 28,969.23 million for various projects, with RMB 5,411.53 million already utilized, representing an investment rate of approximately 18.7%[69]. - The company has established a new Chinese medicine extraction production line with an investment of RMB 7,337 million, which is expected to enhance production capacity[69]. - The company has also invested RMB 9,958 million in upgrading the production capacity of traditional Chinese medicine preparations, with the project expected to be completed by December 1, 2018[69]. - The company has allocated RMB 2,700 million for the construction of a research and development center, aimed at enhancing innovation capabilities[69]. Market and Product Development - The company operates in the traditional Chinese medicine manufacturing industry, focusing on research, development, production, and sales of proprietary Chinese medicine products for urological and gynecological diseases, with over 50 drug production licenses and 13 exclusive varieties[25]. - The company has 11 products in production, with 8 being exclusive products, including leading products like Ningmitai capsules and Kuntai capsules, which are unique in the domestic market[27]. - The company’s products are included in the national medical insurance directory, enhancing their market competitiveness and accessibility[30]. - The company emphasizes the use of local medicinal resources from Guizhou province, which is rich in traditional Chinese medicinal materials, ensuring stable supply[38]. - The company has a strong focus on academic promotion and professional marketing, which has increased trust among clinical medical personnel towards its products[37]. Shareholder Information - The company has a total of 14,798 ordinary shareholders at the end of the reporting period[122]. - The largest shareholder, Guiyang Xintian Biological Technology Development Co., Ltd., holds 43.94% of the shares, totaling 30,265,766 shares[122]. - The second-largest shareholder, Guiyang Jiaxiu Investment Center, holds 10.89% of the shares, totaling 7,500,000 shares[122]. - The company completed a public offering of 17,220,000 shares, increasing total share capital from 51,660,000 shares to 68,880,000 shares[117]. Compliance and Risk Management - The company strictly adhered to compliance management, enhancing internal control systems to mitigate risks and improve operational efficiency[42]. - The company is actively responding to the risks associated with pharmaceutical system reforms and aims to enhance brand influence and negotiation capabilities[80]. - The company has not encountered any major litigation or arbitration matters during the reporting period[91]. - The company has not experienced any significant changes in major risks compared to the previous period[82]. - The company has not engaged in any related party transactions during the reporting period[95]. Environmental Responsibility - The company operates two wastewater treatment stations, with the old plant having a daily processing capacity of 2,000 tons and the new plant 720 tons[110]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[108]. - The company has implemented pollution prevention measures and all environmental facilities are operating normally and meeting discharge standards[109]. - The company has not reported any significant environmental issues or exceedances in pollutant discharge limits[109].